Coya Therapeutics, Inc. Common Stock (COYA)vsRevolution Medicines Inc (RVMD)
COYA
Coya Therapeutics, Inc. Common Stock
$4.38
-3.10%
HEALTHCARE · Cap: $106.03M
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Coya Therapeutics, Inc. Common Stock generates 981% more annual revenue ($8.02M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -270.2%. COYA earns a higher WallStSmart Score of 29/100 (F).
COYA
Avoid29
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.6%
Fair Value
$4.34
Current Price
$4.38
$0.04 premium
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 49.0% year-over-year
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : COYA
The strongest argument for COYA centers on Revenue Growth, Price/Book. Revenue growth of 49.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : COYA
The primary concerns for COYA are EPS Growth, Altman Z-Score, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
COYA profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
COYA is growing revenue faster at 49.0% — sustainability is the question.
RVMD generates stronger free cash flow (-745M), providing more financial flexibility.
Bottom Line
COYA scores higher overall (29/100 vs 24/100) and 49.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coya Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is headquartered in Houston, Texas.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?